Revista de la Facultad de Medicina

Changes in systemic blood pressure by intravitreal bevacizumab

DOI: https://doi.org/10.37345/23045329.v1i25.18

Artículos | Publicado: 2018-07-01

Autores:

  • María Fernanda Fuentes
  • Rodrigo Verdugo

Introduction: The study aimed to evaluate possible differences in previous systemic arterial blood pressure and 24 hours after the application of intravitreal Bevacizumab in patients with various retinopathies. Method: A total of 68 patients were studied with the objective of determining arterial blood pressure before and after the application of intravitreal Bevacizumab. This is a prospective observational cohort study and possible differences were calculated by t-student test for paired samples with an alpha of 0.05. Significant changes of arterial blood pressure were evaluated previous to intravitreal administration and 24 hours after. Results: A total of 68 patients with various retinopathies were studied. Four were excluded because did not meet the inclusion criteria.  Changes in systemic blood pressure showed in an increase of approximately 7.44 mmHg in systolic pressure and an increase of 2.41 mmHg in the diastolic one. Conclusions: Intravitreal Bevacizumab mildly increase systemic blood pressure 24 hours after its use. As already observed in other studies, this is an adverse cause for its use in risk patients.

https://revista-medicina.ufm.edu

Facultad de Medicina de la Universidad Francisco Marroquín

Email: revistamedicina@ufm.edu

ISSN online 2304-5353 / ISSN printed 2304-5329

 

Cómo citar

Changes in systemic blood pressure by intravitreal bevacizumab. (2018). Revista De La Facultad De Medicina, 1(25), 2-6. https://doi.org/10.37345/23045329.v1i25.18